Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase Ib Clinical Study With Extension Phase to Evaluate Safety and Efficacy of Genolimzumab (GB226) in Combination With Fruquintinib in the Treatment of Relapsed or Metastatic NSCLC Patients

Trial Profile

A Phase Ib Clinical Study With Extension Phase to Evaluate Safety and Efficacy of Genolimzumab (GB226) in Combination With Fruquintinib in the Treatment of Relapsed or Metastatic NSCLC Patients

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 29 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fruquintinib (Primary) ; Genolimzumab (Primary)
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions
  • Sponsors Genor Biopharma
  • Most Recent Events

    • 25 Nov 2019 Status changed from not yet recruiting to recruiting.
    • 03 Dec 2018 New trial record
    • 29 Oct 2018 According to a Genor Biopharma media release, the study is expected to begin enrolling patients in China in late 2018. Data from this study may lead to subsequent Phase III registration studies to establish the safety and efficacy of the combination in China.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top